Immunoblots of cleaved PARP, a well-known marker of cellular apoptosis16, indicated that the combination treatment consistently induced more apoptosis relative to other treatments for all melanoma cell lines tested, irrespective of their BRAF or NRAS mutation status (Fig. 2d). The gene discussed is NRAS; the disease is melanoma.